HYPERMAGNESAEMIA
DEFINITION
A serum magnesium concentration above the normal range (typically 0.8
to 1.2 mmol/L, 1.6 to 2.4 mEq/L, 2.0 to 2.6 mg/dL).
TOXIC CAUSES
States of magnesium excess usually result from overzealous therapeutic
administration of magnesium or from conventional doses in the presence
of impaired renal function.
NON-TOXIC CAUSES
Adrenal insufficiency
End-stage renal disease
Familial benign hypocalciuric hypercalcaemia.
Rhabdomyolysis
CLINICAL FEATURES
Magnesium reduces neuromuscular transmission and acts as a central
nervous system depressant. Nausea usually appears at 3 to 5 mEq/L.
Sedation, hypoventilation with respiratory acidosis, decreased deep
tendon reflexes and muscle weakness appear at 4 to 7 mEq/L.
Hypotension, bradycardia and diffuse vasodilatation appear at 5 to 10
mEq/L. Respiratory paralysis occurs at 10 to 15 mEq/L.
DIFFERENTIAL DIAGNOSIS
Bradycardia due to other causes (e.g. beta-adrenoceptor antagonists,
digoxin, myocardial infarction).
Disturbance of consciousness due to other causes (e.g. drug overdose).
Muscle weakness due to other causes (e.g. muscular dystrophies).
RELEVANT INVESTIGATIONS
Serum electrolytes, blood urea, creatinine, glucose and arterial blood
gases are helpful in determining the diagnosis and in evaluating the
severity of this disorder. An ECG may be indicated to assess any
cardiac dysrrhythmias.
TREATMENT
Treatment of hypermagnesaemia is directed firstly at removal of the
source of magnesium and secondly at enhancing removal if the serum
concentration of magnesium poses a threat to survival. Infusion of
calcium will produce a rapid but short-lived reduction in the serum
magnesium and often dramatic improvement in the patient's clinical
condition. High serum concentrations of magnesium in the presence of
impaired renal function may require haemodialysis.
CLINICAL COURSE AND MONITORING
Magnesium concentrations should be monitored during therapeutic
intervention. If the concentration does not return to the normal
range, further correction may be necessary. Fluid balance,
electrolytes, cardiac status and acid-base balance should also be
monitored.
LONG-TERM COMPLICATIONS
None.
AUTHOR(S)/REVIEWERS:
Authors: Tim Meredith and Yeong-Liang Lin
Center for Clinical Toxicology
Vanderbilt University Medical Center
Nashville, USA.
Reviewers: Rio de Janeiro 9/97: J.N. Bernstein, E. Birtanov,
R. Fernando, H. Hentschel, T.J. Meredith, Y. Ostapenko,
P. Pelclova, C.P. Snook, J. Szajewski.